Table 1.
Clinical characteristics according to aPWV groups
| Normal PWV <10 m/s | Increased PWV ≥ 10 m/s | p-value | |
|---|---|---|---|
| n = 64 | n = 42 | ||
| Clinical demographics | |||
| Age | 51.2 ± 14 | 63 ± 12 | <0.001* |
| Male gender (%) | 45.4 | 41.2 | 0.455 |
| BSA (g/m2) | 1.88 ± 0.21 | 1.87 ± 0.22 | 0.906 |
| Cardiovascular risk factors | |||
| BMI (g/m2) | 26.9 ± 5 | 27.8 ± 5.1 | 0.367 |
| eGFR (mL/min/1.73 m2) | 48.95 ± 20.1 | 30.5 ± 15.4 | <0.001* |
| Systolic BP (mmHg) | 127.2 ± 20.4 | 140.5 ± 18.5 | 0.01* |
| Diastolic BP (mmHg) | 77.9 ± 10.6 | 79.5 ± 10.5 | 0.451 |
| Diabetes (%) | 20.3 | 71 | <0.001* |
| Hypertension (%) | 62.5 | 82.8 | <0.001* |
| Family history of IHD (%) | 29.7 | 26.8 | 0.755 |
| Smoking status (%) Current | |||
| Current | 6.3 | 9.8 | 0.295 |
| Ex | 9.4 | 9.8 | |
| Never | 45.3 | 34.1 | |
| Medication | |||
| Aspirin (%) | 28 | 37 | 0.367 |
| Clopidogrel (%) | 2 | 7 | 0.135 |
| ACE-I (%) | 34 | 69 | <0.001* |
| ARBs (%) | 53 | 51 | 0.858 |
| Beta-blockers (%) | 16 | 22 | 0.416 |
| CCB dihydropyridine (%) | 25 | 38 | 0.151 |
| Loop diuretic (%) | 22 | 34 | 0.112 |
| Thiazide diuretic (%) | 2 | 10 | 0.06 |
| Any antihypertensive (%) | 40.1 | 87.2 | |
| Statins (%) | 61 | 80 | 0.110 |
| Prednisolone (%) | 22 | 10 | 0.125 |
| Metformin (%) | 9 | 18 | 0.081 |
| Gliclazide (%) | 9 | 12 | 0.649 |
| Insulin (%) | 8 | 41 | <0.001* |
BSA body surface area; BMI body mass index; GFR glomerular filtration rate, CKD chronic kidney disease; BP blood pressure; ARB angiotensin II receptor blocker; CCB calcium channel blocker; IHD ischemic heart disease; ACE-I angiotensin-converting enzyme inhibitor; ARB angiotensin II receptor blocker
*Statistically significant difference between the two groups